



ASX Announcement

20 October 2016

Pharmaceutical-grade medicinal cannabis manufacturer Creso Pharma commences trading on the ASX

- Leading medicinal cannabis manufacturer Creso Pharma Limited lists on the ASX after successfully raising \$5 million
- IPO significantly oversubscribed with support from high net worth individuals, local and international institutions and retail investors
- Experienced management team with proven track record that brings extensive pharmaceutical industry expertise to the world of medicinal cannabis.
- Creso's product range targets both human and pet treatment markets
- Funds raised to be used for further product development and marketing
- Hemp Industries, a wholly owned subsidiary of Creso Pharma is a revenue generating business with sales in central and Eastern Europe

Creso Pharma Limited (ASX: CPH, or 'the Company') today commenced trading on the Australian Stock Exchange under the ticker code CPH, following a successful Initial Public Offering (IPO) that raised \$5 million.

The IPO, led by EverBlu Capital, was significantly oversubscribed and puts the Company in a strong financial position to further develop its product range and unique delivery technologies that focus on the nutraceutical (food supplement) market for both humans and animals.

The board of Creso Pharma thanks its existing investors, which includes high net worth individuals, local and international institutions and retail investors, and would like to extend a warm welcome to all the new shareholders of the Company.

Creso is the leader in cannabidiol (CBD) innovation. Unlike its rivals, the Company uses full plant extracts with full spectrum cannabinoid blends for improved safety and efficacy. Creso has exclusive worldwide licences to cutting edge Swiss and German drug delivery technologies from global pharmaceutical companies for buccal and sublingual absorption (through the inside of the mouth) of cannabis-based treatments.

Creso's pharmaceutical-grade cannabis and hemp based products and treatments are manufactured to the highest GMP (Good Manufacturing Practice) quality standards.

Wealth of management experience

The Company's founders have a wealth of pharmaceutical and medicinal cannabis industry experience.

CEO and co-founder, Dr. Miri Halperin Wernli, and non-executive director, Dr. Simon Buckingham, have over 25 years' senior management experience each in the global pharmaceutical and biomedical industries. The group's CEO, Dr. Halperin Wernli, will lead Creso through its registered daughter company in Zug, Switzerland.



ABN: 89 609 406 911

Fellow co-founder and Chairman, Boaz Wachtel, is a former managing director of Australia's first publicly traded medical cannabis company and has worked with the Israeli Ministry of Health with the implementation of that country's successful national medical cannabis program.

Creso's board is supported by a team of advisors who collectively have around 100 years of experience in the pharma and finance industry.

This wealth of experience places the Company in a unique position to capitalise on the growing global medical cannabis and hemp sourced market by bringing pharmaceutical expertise to the sector.

Pipeline of opportunities

The Company is well placed to deliver on a number of commercial milestones in the next 12 months and is in final stage of negotiations to secure a distribution agreement that will deliver revenues in the near term.

In addition, the Company is confident in its ability to secure a number of binding Letters of Intent (LOIs) with European and North American partners to progress the development and commercialisation of Creso's products for the animal and human health markets.

"Our debut on the Australian Stock Exchange marks an important step forward in our journey to commercialise our range of innovative products. While the medicinal cannabis industry is booming, there is a notable unmet need in the market for pharmaceutical-grade cannabis/hemp based nutraceutical products," said Boaz Wachtel, Chairman and Co-Founder Creso.

"This is where Creso will excel as we have a management team with the right track record and expertise to develop and deliver trusted treatments for both animal and human health. Creso brings pharmaceutical rigor and expertise to the world of medicinal cannabis."

CEO and Co-Founder Dr. Miri Halperin Wernli added: "My vision is that the future of this industry will be one of parallel tracks, with pharmaceutical-grade cannabinoid drug therapies being developed alongside the advancement of traditional plant-derived cannabis treatments."

For more information please visit our website: www.cresopharma.com

---END---

Investor Enquiries:

Gabriella Hold
M: 0411 364 382
E: gabriella.hold@mcpartners.com.au

Media Enquiries:

Harrison Polites
M: 0409 623 618
E: harrison.polites@mcpartners.com.au

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street,
Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 4371



ABN: 89 609 406 911

About Creso Pharma

Creso Pharma will lead the field of cannabis derived therapeutic grade nutraceutical products for human and animal health. Its leadership team has held senior positions at global pharmaceutical companies. Leveraging science and research and focusing on proprietary innovative Swiss and German delivery mechanisms, Creso Pharma is developing cannabis and hemp derived therapeutic products, manufactured to the highest pharmaceutical GMP standard and delivered to the highest quality levels across the supply chain. Creso is the leader in cannabidiol (CBD) innovation, providing vast therapeutic choices and opportunities to human and animal health medicine. Creso Pharma brings pharmaceutical rigor and expertise to the world of medicinal cannabis.